Item 8.01. Other Events.

Adoption of Pre-Arranged Trading Plans by Directors

Rule 10b5-1 of the Securities Exchange Act of 1934 permits officers and directors of public companies to adopt predetermined written plans for trading specified amounts of company stock when they are not in possession of material nonpublic information in order to gradually diversify their investment portfolios, to minimize the market effect of stock sales by spreading them out over an extended period of time, and to avoid concerns about initiating stock transactions while in possession of material nonpublic information.

United Therapeutics is aware that the following three members of its Board of Directors ("Board") recently entered into prearranged trading plans in accordance with Securities and Exchange Commission Rule 10b5-1 and United Therapeutics' Securities Trades by Company Personnel Policy. The transactions under these plans will be disclosed publicly through Form 144 filings with the Securities and Exchange Commission. Corresponding Form 4 filings will also be completed.

Christopher Causey

The 10b5-1 plan adopted by Christopher Causey on November 20, 2008, involves a market order to sell 1,000 shares of United Therapeutics common stock on the first Thursday of each month beginning December 4, 2008, and ending November 4, 2010, with all such shares acquired through the exercise of employee stock options. Shares will be sold under the plan on the open market at prevailing market prices subject to a minimum price threshold. The plan will expire when the maximum amount of 24,000 shares has been sold or December 4, 2010, whichever first occurs.

R. Paul Gray

The 10b5-1 plan adopted by R. Paul Gray on November 20, 2008, involves a market order to sell 1,000 shares of United Therapeutics common stock on the first Thursday of each month beginning December 4, 2008, and ending November 4, 2010, with all such shares acquired through the exercise of employee stock options.
Shares will be sold under the plan on the open market at prevailing market prices subject to a minimum price threshold. The plan will expire when the maximum amount of 24,000 shares has been sold or December 4, 2010, whichever first occurs.

Christopher Patusky

The 10b5-1 plan adopted by Christopher Patusky on November 21, 2008, involves market orders to sell 5,000 shares of United Therapeutics common stock on September 3, 2009, and 3,333 shares of United Therapeutics common stock on October 1, 2009, with all such shares acquired through the exercise of employee stock options. Shares will be sold under the plan on the open market at prevailing market prices subject to a minimum price threshold. The plan will expire when the maximum amount of 8,333 shares has been sold or the underlying options expire, whichever first occurs.

---